Larkin, A.
13982  Ergebnisse:
Personensuche X
?
1

P.9 Findings of a patient registry for MSUD using coordinat..:

Dolins, K ; Jurecki, E ; Larkin, A
Molecular Genetics and Metabolism.  141 (2024)  - p. 108375 , 2024
 
?
4

P.14 APHENITY extension study dietary phe tolerance assessm..:

Hollander, S ; Bledsoe, A ; Nagy, L...
Molecular Genetics and Metabolism.  141 (2024)  - p. 108380 , 2024
 
?
6

107 Communication deficits at transitions of care:

Walsh, A ; Costello, R ; Larkin, J.
Age and Ageing.  52 (2023)  Supplement_3 - p. , 2023
 
?
8

103P Long-term survivorship rates among previously treated ..:

George, S. ; Larkin, J. ; Chepynoga, K....
Immuno-Oncology and Technology.  20 (2023)  - p. 100575 , 2023
 
?
9

33P Impact of prior treatment on baseline immune biomarkers..:

Ascierto, P.A. ; Tang, H. ; Dolfi, S....
Immuno-Oncology and Technology.  20 (2023)  - p. 100502 , 2023
 
?
10

119O Long-term efficacy and patterns of response of lifileu..:

Medina, T. ; Chesney, J.A. ; Whitman, E....
Immuno-Oncology and Technology.  20 (2023)  - p. 100591 , 2023
 
?
 
?
13

Real-world outcomes of cabozantinib treatment after first-l..:

Nathan, P. ; Allison, J. ; Charnley, N....
European Urology Open Science.  57 (2023)  - p. S238-S239 , 2023
 
?
14

High level review of configuration and reform of Public Hea..:

Cardwell, K ; Broderick, N ; Tyner, B...
European Journal of Public Health.  32 (2022)  Supplement_3 - p. , 2022
 
?
15

87P Infliximab use in patients with checkpoint inhibitor to..:

Zhang, S.H. ; Cartwright, E. ; Mullings, S....
Immuno-Oncology and Technology.  16 (2022)  - p. 100191 , 2022
 
1-15